Bone Marrow Transplantation

Janus Kinase 3 Inhibitors Can Reduce Graft-Versus-Host Severity

Published in Blood Weekly, November 1st, 2001

by Michael Greer, senior medical writer - Researchers in the United States say that drugs that block a key signaling protein may prevent or ameliorate graft-versus-host disease (GvHD) after bone marrow transplantation

Faith M. Uckun and colleagues at the Parker Hughes Institute in St. Paul, Minnesota, conducted a study to evaluate the efficacy of the "rationally designed [Janus kinase 3] JAK3 inhibitor WHI-P131", originally designed to treat Lou Gehrig disease, in a murine model.

In combination with other prophylactic drugs, WHI-P131 provided significant protection against GvHD, they found.

Uckun and coauthors administered 20...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-11-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry